Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C

AIDS

Volumn 22, Issue 1, 2008, Pages 15-21

  Martin Carbonero, Luz ^a   Nuñez, Marina ^a   Mariño, Ana ^b   Alcocer, Federico ^c   Bonet, Llucía ^d   García Samaniego, Javier ^a   López Serrano, Pilar ^e   Cordero, Miguel ^f   Portu, Joseba ^g   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Universidad de La Coruña   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g HOSPITAL TXAGORRITXU   (Spain)

Author keywords

C virus; HIV; Kinetics; Pegylated interferon; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MIXED INFECTION; MULTIVARIATE ANALYSIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIROLOGY; VIRUS DETECTION; VIRUS RESISTANCE;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HOSPITALS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MULTICENTER STUDIES AS TOPIC; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; SPAIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 37349071425     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f1da99     Document Type: Article

References (38)

1. Davis G. Tailoring antiviral therapy in hepatitis C. Hepatology 2006; 43:909-911.
2. National Institutes of Health. Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002; 36:3-20.
3. Hadzyannis S, Sette H, Morgan T, Balan V, Diago M, Marcellin P, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
4. Ferenci P, Fried M, Shiffman M, Smith CI, Marinos G, Goncales FL, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a/ribavirin. J Hepatol 2005; 43:425-433.
5. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103.
6. Jensen D, Morgan T, Marcellin P, Pockros PJ, Reddy KR, Hadzyannis S, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kD)/ribavirin therapy. Hepatology 2006; 43:954-960.
7. Dalgard O, Bjoro K, Hellum K, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260-1265.
8. Von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
9. Mangia A, Santoro R, Minerva N, Ricci G, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-2617.
10. Rockstroh J, Mocroft A, Soriano V, Tural C, Losso M, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
11. Pérez-Olmeda M, Núñez M, Romero M, González J, Castro A, Arribas JR, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 2:1023-1028.
12. Torriani F, Rodriguez-Torres M, Rockstroh J, Lissen E, González-García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
13. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA 2004; 292:2839-2848.
14. Chung R, Andersen J, Volberding P, Robbins GK, Liu T, Sherman K, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
15. Laguno M, Murillas J, Blanco JL, Martínez E, Miguel R, Sánchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-F36.
16. Moreno A, Bárcena R, García-Garzón S, Moreno L, Quereda C, Muriel A, et al. Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-3b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus. JViral Hepat 2006; 13:466-473.
17. Ballesteros A, Fuster D, Planas R, Clotet B, Tural C. Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. J Antimicrob Chemother 2005; 6:824-827.
18. Santin M, Shaw E, Garcia M, Delejido A, de Castro ER, Rota R, et al. Efficacy and safety of pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses 2006; 22:315-320.
19. Soriano V, Perez-Olmeda M, Rios P, Nunez M, Garcia-Samaniego J, Gonzalez-Lahoz J. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses 2004; 20:351-353.
20. Voigt E, Schulz C, Klausen G, Goelz J, Mauss S, Schmutz G, et al. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV coinfected patients. J Infect 2005; 51:245-249.
21. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, et al. Care of patients with hepatitis C and HIV co-infection. Updated recommendations from the HIV-HCV International Panel. AIDS 2004; 18:1-12.
22. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short Statement of the First European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
23. Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005; 10:309-317.
24. Nuñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in the treatment of chronic hepatitis C in HIV-infected patients: the PRESCO Trial. AIDS Res Human Retroviruses 2007; 23:972-982.
25. Soriano V, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Frequency and causes of premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon alpha-2a plus weight-based ribavirin. Antivir Ther, 2007; In press.
26. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140:370-381.
27. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
28. Sherman K, Shire N, Rouster S, Peters M, Koziel M, Chung R, et al. Viral kinetics in hepatitis C or hepatitis C/HIV-infected patients. Gastroenterology 2005; 128:313-327.
29. Martínez-Bauer E, Crespo J, Romero-Gómez M, Moreno-Otero R, Solá R, Tesey N, et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 2006; 43:72-80.
30. Crespo M, Esteban JI, Ribera E, Falco V, Sauleda S, Buti M, et al. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS 2007; 21:477-481.
31. Hopkins S, Lambourne J, Farrell G, McCullagh L, Hennessy M, Clarke S, et al. Role of individualization of HCV therapy duration in HIV/HCV-coinfected individuals. HIV Med 2006; 7:248-254.
32. Zeuzem S, Fried M, Reddy K, Marcellin P, Diago M, Craxi A, et al. Improving the clinical relevance of pretreatment viral load as a predictor of sustained virological response in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2a plus ribavirin. In: 57th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; 27-31 October 2006; Abstract 209.
33. Berg T, Von Wagner M, Hinrichsen H, Heintges T, Buggisch P, Goeser T, et al. Definition of a pretreatment viral load cut-off for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin. In: 57th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; 27-31 October 2006; Abstract 350.
34. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006; 57:815-818.
35. Sanchez-Tapias J, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, et al. Peginterferon-alfa 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-460.
36. Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
37. Uriel A, Moorehead L, Carriero D, Sulkowski M, Dieterich D. The Hepatitis Resource Network Clinical Trials Group. A multicenter, randomized trial of 48 vs 72 weeks of peginterferon-α2b+ribavirin in HIV/HCV co-infected subjects: longer therapy does not correlate with improved sustained virological response. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; 5-8 February 2006; Abstract 854.
38. Fontana R. Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified ? Gastroenterology 2006; 130:1357-1362.